Загрузка...
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy
Targeted inhibition of the oncogenic BCR-ABL1 fusion protein using the ABL1 tyrosine kinase inhibitor imatinib has become standard therapy for chronic myelogenous leukemia (CML), with most patients reaching total and durable remission. However, a significant fraction of patients develop resistance,...
Сохранить в:
| Опубликовано в: : | PLoS One |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5497988/ https://ncbi.nlm.nih.gov/pubmed/28678800 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0179700 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|